RxDoctor Payments Data

Katie Bordonaro

Nurse Practitioner · la Jolla, CANPI 1245633874

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (34.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 68.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $20,091 and has fallen 76.6% since, to $4,701 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,810in general payments, 2019–2025

Across 464 payments — averaging $103.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$33K
  • Boston Scientific$12K
  • Impulse Dynamics (USA) Inc.$1K
  • Abbott$717
  • Biotronik Inc.$511
  • Pfizer$232
  • plus $544 from 10 others

What the payments were for

  • Consulting fees$5,55012%
  • Speaking & faculty fees$13,97329%
  • Travel & lodging$11,82825%
  • Food & beverage$16,46034%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,810 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$188,550
Medicare patients
375
Services billed
2,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$147,860
XareltoRivaroxaban40$50,506
SotalolSotalol Hcl243$2,913
Amiodarone Hcl60$1,101
Flecainide Acetate22$959
Metoprolol Succinate39$735
Metoprolol Tartrate36$234
Furosemide45$190
Potassium Chloride25$138
Amlodipine Besylate11$52
Pantoprazole Sodium24$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$232$147,860152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →